ADC Therapeutics SA

10.30+2.18+26.85%Vol 473.72K1Y Perf -69.36%
Aug 12th, 2022 16:00 DELAYED
BID8.50 ASK12.50
Open8.20 Previous Close8.12
Pre-Market- After-Market10.30
 - -  - -%
Target Price
31.17 
Analyst Rating
Strong Buy 1.25
Potential %
202.62 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     45.45
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
18.05 
Earnings Rating
Market Cap791.14M 
Earnings Date
9th Aug 2022
Alpha-0.06 Standard Deviation0.18
Beta1.29 

Today's Price Range

8.200.00

52W Range

5.5232.00

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
24.10%
1 Month
15.21%
3 Months
39.38%
6 Months
-32.64%
1 Year
-69.36%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ADCT10.302.180026.85
AAPL172.123.63002.15
GOOG122.652.83002.36
MSFT291.914.89001.70
XOM94.000.81000.87
WFC45.940.69001.52
JNJ165.30-1.8400-1.10
FB196.640.99000.51
GE79.931.03001.31
JPM122.131.99001.66
 
ProfitabilityValueIndustryS&P 500US Markets
97.60
-239.20
-235.90
-
-
RevenueValueIndustryS&P 500US Markets
76.66M
1.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.96-0.8412.50
Q01 2022-0.76-0.2271.05
Q04 2021-0.87-0.4548.28
Q03 2021-1.16-0.9319.83
Q02 2021-0.84-0.95-13.10
Q01 2021-1.00-0.6733.00
Q04 2020-0.68-0.73-7.35
Q03 2020-0.77-0.2962.34
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.96
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume473.72K
Shares Outstanding76.81K
Shares Float32.95M
Trades Count5.23K
Dollar Volume4.56M
Avg. Volume307.06K
Avg. Weekly Volume304.87K
Avg. Monthly Volume315.11K
Avg. Quarterly Volume301.21K

ADC Therapeutics SA (NYSE: ADCT) stock closed at 10.3 per share at the end of the most recent trading day (a 26.85% change compared to the prior day closing price) with a volume of 473.72K shares and market capitalization of 791.14M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 138 people. ADC Therapeutics SA CEO is .

The one-year performance of ADC Therapeutics SA stock is -69.36%, while year-to-date (YTD) performance is -49.01%. ADCT stock has a five-year performance of %. Its 52-week range is between 5.52 and 32, which gives ADCT stock a 52-week price range ratio of 18.05%

ADC Therapeutics SA currently has a PE ratio of -3.20, a price-to-book (PB) ratio of 3.83, a price-to-sale (PS) ratio of 8.14, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.40%, a ROC of -55.09% and a ROE of -84.74%. The company’s profit margin is -%, its EBITDA margin is -235.90%, and its revenue ttm is $76.66 Million , which makes it $1.00 revenue per share.

Of the last four earnings reports from ADC Therapeutics SA, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.96 for the next earnings report. ADC Therapeutics SA’s next earnings report date is -.

The consensus rating of Wall Street analysts for ADC Therapeutics SA is Strong Buy (1.25), with a target price of $31.17, which is +202.62% compared to the current price. The earnings rating for ADC Therapeutics SA stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ADC Therapeutics SA has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ADC Therapeutics SA has a Buy technical analysis rating based on Technical Indicators (ADX : 21.24, ATR14 : 0.62, CCI20 : 327.03, Chaikin Money Flow : 0.03, MACD : 0.21, Money Flow Index : 84.48, ROC : 36.06, RSI : 69.22, STOCH (14,3) : 100.00, STOCH RSI : 1.00, UO : 73.37, Williams %R : 0.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ADC Therapeutics SA in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (66.67 %)
4 (66.67 %)
4 (66.67 %)
Moderate Buy
2 (33.33 %)
2 (33.33 %)
2 (33.33 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.25
Strong Buy
1.25

ADC Therapeutics SA

ADC Therapeutics SA is a United States-based clinical-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ADCT-402, ADCT-301, ADCT-602, and ADCT-601.

CEO:

Telephone: +41 216530200

Address: Route de la Corniche 3B, Epalinges 1066, , CH

Number of employees: 138

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

72%28%

Bearish Bullish

70%30%

TipRanks News for ADCT

Wed, 10 Aug 2022 12:36 GMT ADC Therapeutics (ADCT) Receives a Buy from RBC Capital

- TipRanks. All rights reserved.

Mon, 11 Jul 2022 10:17 GMT ADC Therapeutics (ADCT) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Tue, 08 Mar 2022 06:32 GMT Analysts Offer Insights on Healthcare Companies: ADC Therapeutics (ADCT), Bluebird Bio (BLUE) and Oncolytics Biotech (ONCY)

- TipRanks. All rights reserved.

News

Stocktwits